A long-term clinical study using Evenamide (orally taken new drug without masking its strength) to determine its safety, tolerability and efficacy in patients with treatment resistant schizophrenia, not befitting adequately from their current antipsychotic medication - Trial SLCTR_2020_024
Access comprehensive clinical trial information for SLCTR_2020_024 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dr Ravi Anand/Newron Pharmaceuticals S.p.A and is currently Recruiting. The study focuses on Schizophrenia.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2020_024
Phase 2
Recruiting
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2020_024
A long-term clinical study using Evenamide (orally taken new drug without masking its strength) to determine its safety, tolerability and efficacy in patients with treatment resistant schizophrenia, not befitting adequately from their current antipsychotic medication
An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of evenamide as add-on treatment in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their current antipsychotic medication
Study Focus
Interventional
Sponsor & Location
Dr Ravi Anand/Newron Pharmaceuticals S.p.A
India, Italy, Malaysia, Sri Lanka
Timeline & Enrollment
Phase 2
May 03, 2021
N/A
ICD-10 Classifications
Schizophrenia
Simple schizophrenia
Schizophrenia, unspecified
Other schizophrenia
Paranoid schizophrenia
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2020_024
Non-Device Trial